Background: Epidemiological studies substantiated that subjects with elevated lipoprotein(a) [Lp(a)] have a markedly increased cardiovascular risk. Inhibition of proprotein convertase subtilisin/kexin type 9 (PCSK9) lowers both LDL cholesterol (LDL-C) as well as Lp(a), albeit modestly. Effects of PCSK9 inhibition on circulating metabolites such as lipoprotein subclasses, amino acids and fatty acids remain to be characterized. Methods: We performed nuclear magnetic resonance (NMR) metabolomics on plasma samples derived from 30 individuals with elevated Lp(a) (> 150 mg/dL). The 30 participants were randomly assigned into two groups, placebo (N = 14) and evolocumab (N = 16). We assessed the effect of 16 weeks of evolocumab 420 mg Q4W treatment...
Background and aimsFamilial dysbetalipoproteinemia (FDBL) is a rare inborn lipid disorder characteri...
Statin therapy modestly increases new-onset diabetes risk. The effect of PCSK9 inhibition on new-ons...
IMPORTANCE: The PCSK9 inhibitor evolocumab reduced low-density lipoprotein cholesterol and cardiovas...
Background: Epidemiological studies substantiated that subjects with elevated lipoprotein(a) [Lp(a)]...
BACKGROUND: Lipoprotein(a) [Lp(a)] may play a causal role in atherosclerosis. PCSK9 (proprotein conv...
Dirk J Blom,1 Ricardo Dent,2 Rita C Castro,2 Peter P Toth3,4 1Division of Lipidology, Department of ...
ObjectivesThe purpose of this study was assess the effect of evolocumab (AMG 145) on lipoprotein (Lp...
BACKGROUND: Lipoprotein(a) [Lp(a)] may play a causal role in atherosclerosis. PCSK9 (proprotein conv...
Background: Monoclonal antibodies to proprotein convertase subtilisin/kexin type 9 (PCSK9) signific...
The level of low-density lipoprotein cholesterol (LDL-C) reflects the cholesterol carried mainly by ...
BACKGROUND: Lipoprotein(a) [Lp(a)] may play a causal role in atherosclerosis. Proprotein convertase ...
In 2003, clinical observations led to the discovery of the involvement of proprotein convertase subt...
OBJECTIVE: Increased risk of atherosclerotic cardiovascular disease in subjects with type 2 diabetes...
International audienceBackground: Proprotein Convertase Subtilisin/Kexin type 9 inhibitors (PCSK9-I)...
Background: The relationship between cholesterol levels and risk of venous thromboembolism (VTE) is ...
Background and aimsFamilial dysbetalipoproteinemia (FDBL) is a rare inborn lipid disorder characteri...
Statin therapy modestly increases new-onset diabetes risk. The effect of PCSK9 inhibition on new-ons...
IMPORTANCE: The PCSK9 inhibitor evolocumab reduced low-density lipoprotein cholesterol and cardiovas...
Background: Epidemiological studies substantiated that subjects with elevated lipoprotein(a) [Lp(a)]...
BACKGROUND: Lipoprotein(a) [Lp(a)] may play a causal role in atherosclerosis. PCSK9 (proprotein conv...
Dirk J Blom,1 Ricardo Dent,2 Rita C Castro,2 Peter P Toth3,4 1Division of Lipidology, Department of ...
ObjectivesThe purpose of this study was assess the effect of evolocumab (AMG 145) on lipoprotein (Lp...
BACKGROUND: Lipoprotein(a) [Lp(a)] may play a causal role in atherosclerosis. PCSK9 (proprotein conv...
Background: Monoclonal antibodies to proprotein convertase subtilisin/kexin type 9 (PCSK9) signific...
The level of low-density lipoprotein cholesterol (LDL-C) reflects the cholesterol carried mainly by ...
BACKGROUND: Lipoprotein(a) [Lp(a)] may play a causal role in atherosclerosis. Proprotein convertase ...
In 2003, clinical observations led to the discovery of the involvement of proprotein convertase subt...
OBJECTIVE: Increased risk of atherosclerotic cardiovascular disease in subjects with type 2 diabetes...
International audienceBackground: Proprotein Convertase Subtilisin/Kexin type 9 inhibitors (PCSK9-I)...
Background: The relationship between cholesterol levels and risk of venous thromboembolism (VTE) is ...
Background and aimsFamilial dysbetalipoproteinemia (FDBL) is a rare inborn lipid disorder characteri...
Statin therapy modestly increases new-onset diabetes risk. The effect of PCSK9 inhibition on new-ons...
IMPORTANCE: The PCSK9 inhibitor evolocumab reduced low-density lipoprotein cholesterol and cardiovas...